Test Price
2,800 AED✅ Home Collection Available
LHX3 Gene Combined Pituitary Hormone Deficiency Type 3 (CPHD3) Genetic Test | DNA Labs UAE
Executive Summary & Core Metrics
Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing
Premium Logistics
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM)
Clinical Guidance
Post‑Test Telephonic Interpretation Session by a DHA‑Licensed Specialist
Insurance
Direct Billing Verification via WhatsApp: +971 54 548 8731
Executive Summary: The LHX3 NGS test detects pathogenic variants in the LHX3 gene, enabling accurate diagnosis of combined pituitary hormone deficiency type 3 (CPHD3), a rare genetic disorder affecting growth, metabolism, and development. The test empowers endocrinologists, general physicians, and primary care doctors to initiate early, personalized hormone replacement and multidisciplinary care.
Test Overview & Methodology
The LHX3 NGS test utilizes next-generation sequencing (NGS) to comprehensively analyze the LHX3 gene, including all exons, introns, and flanking regions. This method provides high analytical sensitivity for single nucleotide variants, small insertions/deletions, and copy number alterations in a single assay, offering a definitive molecular diagnosis for combined pituitary hormone deficiency type 3.
Comparison with Alternative Approaches
| Feature | Our LHX3 NGS Test | Single‑Gene PCR / MLPA |
|---|---|---|
| Methodology | Next‑Generation Sequencing (full gene & flanking introns) | Targeted mutation analysis / deletion/duplication only |
| Variant Detection | SNVs, indels, copy number changes in a single assay | Limited to known hotspots or specific exon deletions |
| Turnaround Time | 3–4 weeks | 4–6 weeks (if multiple tests required) |
| Clinical Confidence | 99.9% analytical sensitivity, ISO 9001:2015 accredited | May miss rare or novel variants |
| Sample Types | Whole blood, extracted DNA, or FTA card | Whole blood (EDTA) |
Physician Insight & Safety Protocols
From Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403): “This NGS‑based LHX3 gene test is a definitive molecular tool that, when correlated with clinical and biochemical findings, guides life‑saving hormone replacement. Genetic results require expert interpretation and should never be used alone to alter treatment. It is essential to discuss all findings with a qualified specialist before making any therapeutic adjustments.”
Clinical Advisory: Interpretation & Follow‑Up
Post‑Test Recommendations
- All results must be reviewed by a DHA‑licensed physician to exclude incidental findings or variants of uncertain significance.
- Do not discontinue or alter prescribed hormone therapy without consulting your endocrinologist.
- Genetic counselling is strongly recommended before and after testing to discuss family implications and reproductive options.
Exclusion Criteria & Emergency Red Flags
Patient Safety Considerations
- Exclusion: Inability to provide a biological sample; recent allogeneic blood transfusion (within 30 days); acute febrile illness at time of collection.
- Red Flags – seek immediate medical attention: Sudden severe headache, visual field defect, hypotension, or signs of adrenal crisis (vomiting, confusion, collapse) in a patient with suspected pituitary deficiency.
- Minors: Requires parental/legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the purpose of the LHX3 gene test?
This test identifies mutations in the LHX3 gene causing combined pituitary hormone deficiency type 3, enabling early diagnosis and personalized management. The result guides endocrinologists in selecting the correct hormone replacement and surveillance for associated features such as neck anomalies and skeletal dysplasia.
2. How is the sample collected, and is home service available in the UAE?
A trained phlebotomist collects a blood sample via painless venipuncture at your home between 8 AM and 11 PM, or you may provide extracted DNA or an FTA card. The sample is transported under strict cold‑chain conditions to our ISO‑certified central lab in accordance with UAE data privacy laws.
3. When will I receive the results, and who will explain them?
Results are delivered within 3 to 4 weeks in a comprehensive PDF report, followed by a telephonic consultation with a DHA‑licensed expert to interpret the findings. Genetic counselling is strongly recommended before testing to draw a detailed family pedigree; our team assists in arranging this session and verifying insurance coverage via WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
Compliance Framework
This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient data is encrypted, access‑controlled, and handled strictly in accordance with UAE health data protection standards. The laboratory holds ISO 9001:2015 certification and is licensed by the Dubai Health Authority (DHA).
Clinical & Logistical Metadata
| Test Name | LHX3 Gene Combined Pituitary Hormone Deficiency Type 3 (CPHD3) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card |
| Methodology Used | Next‑Generation Sequencing (NGS) – full gene with flanking introns |
| ICD-10-CM Code | E23.0 |
| LOINC Code | 92309-2 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians